此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

胎盘生物学在健康与疾病中的作用

2026年11月6日 更新者:University of Oxford

Pre-eclampsia (PET) is a condition characterised by high blood pressure and damage to other organs, and is a leading cause of maternal and fetal complications such as fetal growth restriction (FGR). Gestational diabetes mellitus (GDM) involves abnormal blood sugar levels during pregnancy and can have both short and long-term impacts on the health of the mother and child. Both conditions are linked to placental dysfunction but the precise mechanisms behind these links remain unclear.

A major focus of this study is on extracellular vesicles (EVs) which are tiny, bubble-like particles released by the placenta into the mother's and baby's bloodstreams. These EVs act as messengers, carrying proteins, lipids and genetic material that can influence how cells function, even in parts of the body far from the placenta. Notably, the number and content of these EVs change in conditions like PET and GDM, suggesting they may play a role in the development of these complications.

This single-site, observational, laboratory study aims to investigate how these EVs contribute to maternal health and disease. To enable analysis across different physiological and pathological conditions pregnant participants with healthy pregnancies, pregnancies predisposed to PET and pregnancies complicated by GDM, FGR and PET will be recruited alongside healthy non-pregnant controls. Recruitment will be from the Oxford University Hospitals NHS Foundation Trust and the Nuffield Department of Women's and Reproductive Health, University of Oxford (who fund the research). Demographic and clinical data will be collected as well as blood, urine, breath, voice, placenta, umbilical cord, umbilical cord blood, amniotic fluid and/or uterine vein blood samples.

Through examining EV content and function, it is hoped a better understanding of their role in pregnancy complications will be gained, including their potential as non-invasive biomarkers for early detection and targeted treatments, improving outcomes for mothers and babies worldwide.

研究概览

详细说明

The study is a non-interventional, observational study focused on sample collection and laboratory-based analyses to investigate the role of placental EVs and soluble factors in maternal and fetal health. The study will focus on understanding the molecular mechanisms underlying pre-eclampsia, gestational diabetes mellitus and fetal growth restriction, with the ultimate aim of identifying biomarkers and therapeutic targets. To achieve this, the study will recruit participants with healthy, pathological and predisposed pregnancies alongside non-pregnant healthy controls.

研究类型

观察性的

注册 (估计的)

1000

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

女性

取样方法

非概率样本

研究人群

This study will recruit a diverse cohort of pregnant and non-pregnant participants to enable analysis of placental EVs and soluble factors across different physiological and pathological conditions.

Participants will include:

  • Pregnant women with pre-eclampsia, gestational diabetes mellitus or fetal growth restriction to allow the study of disease-specific alterations in EVs and systemic responses.
  • Pregnant women predisposed to pre-eclampsia to provide insights into risk factors and early-stage changes, aiding in biomarker discovery for prediction and prevention.
  • Pregnant women with healthy pregnancies to understand normal EV release and immune regulation.
  • Non-pregnant women to provide critical baseline data to differentiate the effects of pregnancy from underlying physiological processes.

Pregnant participants may be recruited at any gestational stage to ensure a comprehensive coverage of pregnancy progression.

描述

Inclusion Criteria:

  • Female, aged 18 years or above

  • Willing and able to give informed consent for participation in the study

  • Able to read and understand written and spoken English to comprehend study materials and give informed consent

  • Non-pregnant women in good general health OR pregnant women who fall into one of the following:

    • Healthy pregnancy
    • Pre-eclampsia (PET) - defined by clinical diagnostic criteria, including hypertension and proteinuria
    • Gestational diabetes mellitus (GDM) - diagnosed by standard glucose tolerance tests during pregnancy
    • Fetal growth restriction (FGR) - diagnosed based on fetal weight or Doppler abnormalities
    • Predisposed to PET - high-risk factors for PET such as maternal type 1 or type 2 diabetes, autoimmune diseases or multiple pregnancies

Exclusion Criteria:

  • Non-pregnant participants with active health conditions that could confound study outcomes
  • Pregnant participants with conditions unrelated to PET, GDM or FGR that could influence EV profiles e.g. active infections or malignancies

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:OTHER
  • 时间观点:OTHER

队列和干预

团体/队列
干预/治疗
被诊断为先兆子痫的孕妇

There are no interventions for this study

被诊断患有妊娠期糖尿病的孕妇

There are no interventions for this study

被诊断为胎儿生长受限的孕妇

There are no interventions for this study

健康孕妇

There are no interventions for this study

健康的非妊娠女性

There are no interventions for this study

易患先兆子痫的孕妇

There are no interventions for this study

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Enhanced understanding of the molecular and cellular mechanisms linking placental EVs to maternal systemic inflammation in PET and GDM.
大体时间:Baseline and at delivery

Quantitative (number of particles/ml) and qualitative differences (protein cargo) in EV profiles

Baseline and at delivery

次要结果测量

结果测量
措施说明
大体时间
Quantitative and qualitative differences in inflammatory immune cells
大体时间:baseline and delivery

Quantitative (cells/ml) and qualitative (protein and RNA composition/mg cell) will be measured

baseline and delivery
Sensitivity, specificity and predictive value of EVs for identifying PET, GDM and other pregnancy complications
大体时间:Baseline and delivery

Standard statistical analysis of EV parameters against clinical endpoints to derive sensitivity, specificity and PPV/NPV in these disease conditions

Baseline and delivery

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年12月16日

初级完成 (估计的)

2030年5月31日

研究完成 (估计的)

2030年5月31日

研究注册日期

首次提交

2025年12月10日

首先提交符合 QC 标准的

2026年3月9日

首次发布 (实际的)

2026年3月13日

研究记录更新

最后更新发布 (实际的)

2026年11月9日

上次提交的符合 QC 标准的更新

2026年11月6日

最后验证

2025年12月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅